172 related articles for article (PubMed ID: 35739280)
21. EWS-FLI1 positively regulates autophagy by increasing ATG4B expression in Ewing sarcoma cells.
Lu Q; Zhang Y; Ma L; Li D; Li M; Li J; Liu P
Int J Mol Med; 2017 Oct; 40(4):1217-1225. PubMed ID: 28902354
[TBL] [Abstract][Full Text] [Related]
22. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.
Katschnig AM; Kauer MO; Schwentner R; Tomazou EM; Mutz CN; Linder M; Sibilia M; Alonso J; Aryee DNT; Kovar H
Oncogene; 2017 Oct; 36(43):5995-6005. PubMed ID: 28671673
[TBL] [Abstract][Full Text] [Related]
23. Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells.
El Beaino M; Liu J; Wasylishen AR; Pourebrahim R; Migut A; Bessellieu BJ; Huang K; Lin PP
BMC Cancer; 2020 Jan; 20(1):3. PubMed ID: 31898537
[TBL] [Abstract][Full Text] [Related]
24. Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in Ewing sarcoma cells.
Agra N; Cidre F; García-García L; de la Parra J; Alonso J
PLoS One; 2013; 8(6):e66281. PubMed ID: 23750284
[TBL] [Abstract][Full Text] [Related]
25. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors.
Li Y; Li X; Fan G; Fukushi J; Matsumoto Y; Iwamoto Y; Zhu Y
Cancer Lett; 2012 Jul; 320(1):14-22. PubMed ID: 22266186
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer.
Bilke S; Schwentner R; Yang F; Kauer M; Jug G; Walker RL; Davis S; Zhu YJ; Pineda M; Meltzer PS; Kovar H
Genome Res; 2013 Nov; 23(11):1797-809. PubMed ID: 23940108
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
[TBL] [Abstract][Full Text] [Related]
28. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
29. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
30. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
[TBL] [Abstract][Full Text] [Related]
31. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
32. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.
Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ
Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061
[TBL] [Abstract][Full Text] [Related]
33. EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Issaq SH; Mendoza A; Kidner R; Rosales TI; Duveau DY; Heske CM; Rohde JM; Boxer MB; Thomas CJ; DeBerardinis RJ; Helman LJ
Mol Cancer Ther; 2020 Jul; 19(7):1520-1529. PubMed ID: 32371575
[TBL] [Abstract][Full Text] [Related]
34. EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.
Zhou Z; Yu L; Kleinerman ES
Cancer; 2014 Feb; 120(4):579-88. PubMed ID: 24415532
[TBL] [Abstract][Full Text] [Related]
35. Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma.
Knezevich SR; Hendson G; Mathers JA; Carpenter B; Lopez-Terrada D; Brown KL; Sorensen PH
Hum Pathol; 1998 Mar; 29(3):289-94. PubMed ID: 9496833
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells.
Nozawa S; Ohno T; Banno Y; Dohjima T; Wakahara K; Fan DG; Shimizu K
J Biol Chem; 2005 Jul; 280(30):27544-51. PubMed ID: 15919668
[TBL] [Abstract][Full Text] [Related]
37. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
38. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
[TBL] [Abstract][Full Text] [Related]
40. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]